The TTPH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TTPH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TTPH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TTPH Detailed Price Forecast - CNN Money||View TTPH Detailed Summary - Google Finance|
|View TTPH Detailed Summary - Yahoo! Finance||View TTPH Stock Research & Analysis - Zacks.com|
|View TTPH Trends & Analysis - Trade-Ideas||View TTPH Major Holders - Barrons|
|View TTPH Call Transcripts - NASDAQ||View TTPH Breaking News & Analysis - Seeking Alpha|
|View TTPH Annual Report - CompanySpotlight.com||View TTPH OTC Short Report - OTCShortReport.com|
|View TTPH Fundamentals - TradeKing||View TTPH SEC Filings - Bar Chart|
|View Historical Prices for TTPH - The WSJ||View Performance/Total Return for TTPH - Morningstar|
|View the Analyst Estimates for TTPH - MarketWatch||View the Earnings History for TTPH - CNBC|
|View the TTPH Earnings - StockMarketWatch||View TTPH Buy or Sell Recommendations - MacroAxis|
|View the TTPH Bullish Patterns - American Bulls||View TTPH Short Pain Metrics - ShortPainBot.com|
|View TTPH Stock Mentions - StockTwits||View TTPH Stock Mentions - PennyStockTweets|
|View TTPH Stock Mentions - Twitter||View TTPH Investment Forum News - Investor Hub|
|View TTPH Stock Mentions - Yahoo! Message Board||View TTPH Stock Mentions - Seeking Alpha|
|View Insider Transactions for TTPH - SECform4.com||View Insider Transactions for TTPH - Insider Cow|
|View TTPH Major Holdings Summary - CNBC||View Insider Disclosure for TTPH - OTC Markets|
|View Insider Transactions for TTPH - Yahoo! Finance||View Institutional Holdings for TTPH - NASDAQ|
|View TTPH Stock Insight & Charts - FinViz.com||View TTPH Investment Charts - StockCharts.com|
|View TTPH Stock Overview & Charts - BarChart||View TTPH User Generated Charts - Trading View|
Analysts’ Ratings for Sarepta Therapeutics and Peers in April
Posted on Friday April 20, 2018
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
Tetraphase Pharmaceuticals’ Cash Flow and Price Performance
Posted on Thursday April 19, 2018
Tetraphase Pharmaceuticals (TTPH) posted $98.0 million in operating expenses in fiscal 2017, compared with $63.7 million in fiscal 2016. This $34.3 million rise resulted from increased expenses related to the company’s eravacycline Phase 3 studies. Other primary factors included higher drug manufacturing and nonclinical costs in support of its New Drug Application (or NDA) and precommercialization activities for eravacycline.
Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
Posted on Thursday April 19, 2018
Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced two data presentations at the 38th Annual Meeting of the Surgical Infection Society (SIS), taking place April 22-25, at the Four Seasons in Westlake Village, CA. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is in development for the treatment of complicated intra-abdominal infections (cIAI). “Data presented at SIS’s Annual Meeting demonstrate eravacycline’s potent in vitro activity from a total of 7,815 single-patient clinical isolates collected during a four-year period from U.S. hospitals,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase Pharmaceuticals.
Exploring Tetraphase Pharmaceuticals’ Financial Performance
Posted on Wednesday April 18, 2018
Tetraphase Pharmaceuticals (TTPH) generated contract and grant revenues of $9.6 million in fiscal 2017 compared with $5.1 million in fiscal 2016. Until now, the primary source of revenues for the company has been US government contracts.